Similar companies
Income Statement (USD)
| Q3 '24 | QoQ | |
|---|---|---|
| Revenue | 467M | 28.7% |
| Gross Profit | 338M | 51.4% |
| Cost of Revenue | 129M | 7.6% |
| Operating expense | 353M | 10.7% |
| Net Income | 34M | 420.3% |
| EBITDA | 40M | 107.9% |
Balance Sheet (USD)
| Q3 '24 | QoQ | |
|---|---|---|
| Total Assets | 3.6B | 5.1% |
| Total Liabilities | 2.38B | 1.3% |
| Total Equity | 1.22B | 13.4% |
| Shares Outstanding | 95M | 0.2% |
Cash Flow (USD)
| Q3 '24 | QoQ | |
|---|---|---|
| Cash from operations | -71M | 573.2% |
| Cash from investing | -129M | 30.7% |
| Cash from financing | 14M | 65.5% |
EPS
Financial Highlights for Sarepta Therapeutics in Q3 '24
Sarepta Therapeutics reported a revenue of 467M, which is a 28.7% change from the previous quarter. An increase in revenue typically indicates growing demand for the company's products or services. This positive change in revenue is a good sign, suggesting that the company's sales are moving in the right direction.
Gross Profit stood at 338M, marking a 51.4% change since the last quarter. Gross profit showcases the efficiency in production and sales processes.
Cost of Revenue was 129M, a -7.6% difference from the previous quarter. A rising cost of revenue may suggest increased production or sales costs, which can impact margins. However, if accompanied by a proportionate rise in revenue, it could indicate scaling operations.
Operating Expenses for this period were 353M, showing a 10.7% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was 34M, showing a 420.3% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
The company's EBITDA for the quarter was 40M, showing a 107.9% change from the previous period. EBITDA gives insight into the company's operational profitability, excluding non-operating expenses like interest and taxes. A rising EBITDA indicates strong operational performance, while a declining EBITDA may signal operational challenges or increased costs.
It was a positive quarter for Sarepta Therapeutics with growth in revenue, gross profit, and net income. Higher operating expenses might indicate increased investments or potential inefficiencies.
